FDA approves new UTI antibiotic after 30 years

Officials from the Trump administration have responded to concerns about a group text that mistakenly included a journalist discussing U.S. military plans. During a heated Senate Intelligence Committee hearing, the topic stirred debate as Democrats claimed it could endanger national security. The group text reportedly included top officials, including the National Intelligence Director and CIA Director. While some officials, like CIA Director John Ratcliffe, claimed the chat was lawful, critics argued otherwise. National security adviser Michael Waltz took responsibility for the mistake and emphasized that it should not be blamed on a staffer. Meanwhile, former President Trump supported Waltz, downplaying the incident as a minor issue. In other news, the U.S. has paused green card processing for certain applicants to enhance vetting procedures, particularly for those who have been granted asylum. This decision comes as part of a broader effort to ensure thorough checks on immigrants, as mandated by an executive order from Trump’s first day in office. Experts suggest this could lead to delays and increased costs in processing applications. Additionally, the FDA has approved a new antibiotic for treating urinary tract infections (UTIs). Called Bujepa, this is the first new class of antibiotics approved for UTIs in nearly three decades. The drug targets E. coli bacteria, which have become resistant to existing treatments. Bujepa will be available later this year for women and girls aged 12 and older.